We are live on
!
Find out more
Corvus Pharmaceuticals
CRVS
CRVS
55 hedge funds and large institutions have $288M invested in Corvus Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 10 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
170% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 10
59% more capital invested
Capital invested by funds: $180M → $288M (+$107M)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
3.87% more ownership
Funds ownership: 82.79% → 86.65% (+3.9%)
2% more funds holding
Funds holding: 54 → 55 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Holders
55
Holders Change
+1
Holders Change %
+1.85%
% of All Funds
1.26%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
7
Increased
27
Reduced
10
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.1M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$14.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.1M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$11.1M |
| 5 |
ASP
Adams Street Partners
Chicago,
Illinois
|
+$5.56M |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$4.83M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.12M |
| 3 |
JP Morgan Chase
New York
|
-$258K |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$186K |
| 5 |
SIM
Spark Investment Management
New York
|
-$167K |
